Evidence-Based ADHD Treatment Guidelines

First-Line Pharmacotherapy

The American Academy of Child and Adolescent Psychiatry recommends stimulant medications, such as methylphenidate and amphetamines, as first-line pharmacotherapy for ADHD, with demonstrated efficacy in 70-80% of patients and large effect sizes for reducing core ADHD symptoms 1, 2.
Methylphenidate formulations and lisdexamfetamine work through dopamine and norepinephrine reuptake inhibition, directly enhancing prefrontal cortex efficiency and optimizing executive and attentional function 3.
Long-acting stimulant formulations are strongly preferred over short-acting preparations due to better medication adherence, lower rebound risk, more consistent symptom control throughout the day, and reduced diversion potential 1, 2.

If methylphenidate at adequate dosage and duration produces no desired benefit, lisdexamfetamine should be the next option before considering non-stimulants, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 4.

The American Academy of Child and Adolescent Psychiatry recommends non-stimulants, such as atomoxetine, guanfacine extended-release, and clonidine extended-release, as second-line therapy, with smaller effect sizes compared to stimulants 1, 5.
Atomoxetine provides "around-the-clock" effects but requires 6-12 weeks until full effects are observed, compared to rapid onset with stimulants, and has a moderate strength of evidence 1, 5.
Alpha-2 adrenergic agonists, such as guanfacine and clonidine, require 2-4 weeks for effect and have effect sizes around 0.7, with somnolence/sedation as frequent adverse effects, and a low to moderate strength of evidence 1, 2.

The American Academy of Pediatrics recommends monitoring height, weight, pulse, and blood pressure under stimulant therapy, with a high strength of evidence 1, 2.
Suicidality and clinical worsening require monitoring with atomoxetine, with a moderate strength of evidence 1, 5.